Infographic:AHA-ACC 2026 Guidelines for Acute Pulmonary Embolism

The 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults represents the first de novo joint clinical practice guideline dedicated exclusively to acute PE from the American Heart Association and the American College of Cardiology. Published simultaneously in Circulation and JACC on February 19, 2026, this landmark document introduces a transformative five-tiered AHA/ACC Acute Pulmonary Embolism Clinical Category system (Categories A through E), replaces traditional binary risk classification with a nuanced physiopathological framework, formalizes Pulmonary Embolism Response Teams (PERTs) as a Class 1 recommendation, and positions direct oral anticoagulants (DOACs) as the preferred anticoagulant modality. This essay provides a detailed analysis of the guideline, its clinical insights, implementation challenges, and implications for modern practice.

1. Introduction and Epidemiological Context

Acute pulmonary embolism (PE) is a sudden, life-threatening obstruction of one or more pulmonary arteries by a thrombus, most commonly originating from the deep venous system of the lower extremities or pelvis. As a subset of venous thromboembolism (VTE), acute PE constitutes a major cardiovascular emergency with significant morbidity and mortality. According to data cited in the 2026 AHA Heart Disease and Stroke Statistics, approximately 470,000 individuals are hospitalized with PE in the United States annually, with roughly one in five high-risk patients dying from the condition. These sobering figures underscore the urgent need for standardized, evidence-based guidelines governing every phase of care, from initial presentation through long-term follow-up.

For decades, the management of acute PE was guided primarily by institutional protocols, regional practices, and extrapolations from broader VTE research. No dedicated first-party guideline from the American Heart Association (AHA) or American College of Cardiology (ACC) existed — a gap that has now been decisively addressed. The 2026 guideline is the product of a multisociety collaboration encompassing ten professional organizations, representing emergency medicine, pulmonology, cardiology, vascular medicine, interventional radiology, hospital medicine, and nursing. A comprehensive literature search spanning February to October 2024 formed the evidence base, drawing from MEDLINE, EMBASE, the Cochrane Library, and additional databases.

The guideline explicitly recognizes that PE management is inherently multidisciplinary, crossing emergency departments, inpatient settings, and outpatient clinics. By synthesizing the evidence across these domains and translating it into actionable recommendations, the writing committee has produced what may fairly be described as a watershed document in cardiovascular medicine.

 

2. The AHA/ACC Acute PE Clinical Categories: A Paradigm Shift

The most impactful innovation in the 2026 guideline is the introduction of the AHA/ACC Acute Pulmonary Embolism Clinical Categories — a five-tiered classification scheme designated Categories A through E, with subcategories. This system fundamentally replaces the traditional binary or ternary risk stratification models (i.e., low-, intermediate-, and high-risk) that relied predominantly on hemodynamic instability as the primary determinant.

The new framework is integrative and physiopathological in its orientation, incorporating clinical severity scores, biomarker levels, right ventricular (RV) size and function on imaging, hemodynamic parameters, and respiratory compromise. Rather than anchoring treatment decisions to anatomical clot burden — a limitation of older approaches — the system focuses on the functional and hemodynamic impact of the embolus on the cardiopulmonary system.

Category A — Asymptomatic PE

Category A describes patients with confirmed PE who are entirely asymptomatic. The guideline makes a clinically significant recommendation that these individuals can be safely discharged from the emergency department without hospitalization. This reflects an evolving body of evidence suggesting that incidentally detected PE, often found during cancer staging or post-procedural imaging, carries a substantially lower short-term mortality risk than symptomatic PE. The clinical insight here is profound: not every PE diagnosis mandates admission, and appropriate outpatient anticoagulation with structured follow-up is both safe and resource-efficient.

Category B — Symptomatic Low-Severity PE

Category B encompasses patients who are symptomatic but have low clinical severity scores — typically a Pulmonary Embolism Severity Index (PESI) class I or II, a simplified PESI (sPESI) score of zero, or a Hestia score below 1. Early hospital discharge is generally recommended for these patients, provided they have immediate access to anticoagulant medications and reliable, expert follow-up. This recommendation operationalizes the growing evidence base favoring outpatient PE management in appropriately selected patients, reducing unnecessary hospitalization and its associated complications.

Category C — Elevated Clinical Severity with or without RV Involvement

Category C captures symptomatic patients with elevated clinical severity scores (PESI class III-V, sPESI ≥1, or Hestia ≥1), with or without cardiopulmonary dysfunction, elevated biomarkers, or RV dysfunction on imaging. These patients require hospitalization to optimize management. Notably, the use of advanced interventional therapies in Category C carries uncertain benefit, and any such use must follow clinical progression and multidisciplinary deliberation within a structured PERT. This reflects a critical clinical insight: RV dysfunction alone, without hemodynamic compromise, should not trigger reflexive escalation to catheter-based or surgical therapies.

Categories D and E — Incipient and Established Cardiopulmonary Failure

Categories D and E represent a spectrum of deteriorating hemodynamics. Category D defines patients with incipient cardiopulmonary failure, while Category E identifies those with established cardiopulmonary failure characterized by persistent hypotension. The subcategories (D1, D2, E1) reflect gradations in severity. Advanced therapies — including systemic thrombolysis, catheter-directed thrombolysis (CDT), mechanical thrombectomy (MT), and surgical embolectomy — are considered reasonable for Category E1 patients and may be considered for Category D1-D2 patients. The clinical distinction between Categories D and E guides both the urgency and modality of escalation, providing clinicians with a precise therapeutic roadmap where none previously existed.

 

3. Diagnostic Framework: From Pre-Test Probability to Advanced Imaging

The 2026 guideline articulates a structured, evidence-driven diagnostic algorithm. For patients presenting with symptoms and signs suggestive of PE, initial risk stratification using validated clinical decision rules is the recommended starting point. When the pre-test clinical probability of acute PE is assessed as low or intermediate (less than 50%), D-dimer measurement is indicated as the next step. A normal D-dimer level effectively excludes PE without the need for imaging, particularly in low-probability settings.

When D-dimer is elevated, or when clinical probability is deemed high (greater than 50%), imaging is required. The guideline firmly establishes computed tomography pulmonary angiography (CTPA) as the standard imaging modality for diagnosing or excluding acute PE. CTPA offers high diagnostic accuracy, comprehensive anatomical visualization of thrombus location and burden, and wide availability across emergency settings. For patients who cannot undergo CTPA — such as those with allergy to iodinated contrast agents or significant renal impairment — ventilation-perfusion (V/Q) scintigraphy represents the recommended alternative.

A notable clinical insight embedded in the diagnostic framework is the guideline’s acknowledgment that imaging should not be reflexively ordered in every patient, but rather guided by pre-test probability and biomarker findings. Overutilization of CTPA carries risks including radiation exposure, contrast nephropathy, and the detection of incidental, clinically insignificant PE. The guideline’s tiered approach promotes both diagnostic precision and patient safety.

Echocardiography — particularly bedside transthoracic echocardiography — is highlighted as a valuable adjunct in hemodynamically unstable patients where CTPA cannot be safely performed, providing rapid assessment of RV function, septal bowing, and the McConnell sign. Additionally, RV-to-LV diameter ratio on CTPA is recognized as an important quantitative marker of RV strain with prognostic implications.

 

4. Anticoagulation Therapy: Cornerstone and Nuance

4.1 Initiation and Agent Selection

Anticoagulation remains the therapeutic cornerstone of acute PE management. The guideline issues a Class 1 recommendation that anticoagulation therapy be initiated in all patients with confirmed acute PE who do not have an absolute contraindication, with the explicit goal of preventing recurrent VTE and death.

For patients requiring initial parenteral anticoagulation (typically those in Categories C1 through E1), low-molecular-weight heparin (LMWH) is recommended over unfractionated heparin (UFH) as a Class 1 recommendation. This preference is based on evidence demonstrating equivalent or superior efficacy, lower rates of major bleeding, greater predictability of anticoagulation effect, and the convenience of subcutaneous administration without the need for continuous infusion monitoring. UFH retains its role in patients with severe renal insufficiency, those who may require urgent reversal, or those undergoing interventional procedures.

For oral anticoagulation, the guideline issues a strong Class 1 recommendation in favor of DOACs — specifically rivaroxaban, apixaban, edoxaban, and dabigatran — over vitamin K antagonists (VKAs) such as warfarin. This recommendation is grounded in pivotal trial evidence demonstrating that DOACs are non-inferior to warfarin in preventing recurrent VTE while offering significantly lower rates of major bleeding, particularly intracranial hemorrhage. The practical advantages of DOACs — fixed dosing, no routine monitoring, fewer drug and food interactions — further support their adoption as first-line therapy.

4.2 Special Populations

The guideline dedicates careful attention to populations in whom standard DOAC therapy may be inappropriate or require modification:

• Pregnancy: DOACs and warfarin are classified as potentially harmful during pregnancy due to risk of fetal anomalies and miscarriage (Class 3 — Harm). LMWH or UFH are recommended as safe alternatives for pregnant patients with acute PE.
• Antiphospholipid Antibody Syndrome (APS): In patients with confirmed thrombotic APS, a VKA is recommended in preference to a DOAC given evidence of inferior outcomes with DOACs in this population (Class 1, Level of Evidence A).
• Chronic Kidney Disease: For mild-to-moderate CKD (stages 2-3), DOACs are recommended over VKAs for their superior bleeding profile. In severe CKD (stages 4-5) or end-stage renal disease on hemodialysis, the relative benefit of apixaban versus VKA remains uncertain (Class 2b).
• Obesity: In patients with BMI greater than 30 kg/m2, DOACs are preferred over VKAs. In Class III obesity (BMI >40 kg/m2) receiving LMWH, dose reduction may be considered to mitigate bleeding risk.
• Cancer-Associated PE: DOACs are emerging as preferred agents over LMWH in cancer patients, though individual tumor type, bleeding risk, and drug interactions require careful individual assessment.

 

4.3 Duration of Anticoagulation

One of the most clinically significant recommendations pertains to anticoagulation duration. The guideline states that for patients experiencing a first acute PE without a major reversible risk factor (such as surgery or trauma), or in the presence of persistent risk factors, continuation of anticoagulation beyond the initial treatment phase of 3-6 months into the extended phase is recommended. This represents a meaningful shift from prior practice patterns that often defaulted to discontinuation after 3-6 months, and it reflects accumulating evidence that extended-phase anticoagulation substantially reduces recurrence risk without proportionate increases in serious bleeding.

Periodic reassessment of the risk-benefit balance of continued anticoagulation is mandated at each follow-up visit, taking into account changes in bleeding risk, patient preferences, and thromboembolic risk factors.

5. Advanced Therapies: Expanding the Interventional Toolkit

One of the most consequential developments in acute PE management over the past decade has been the proliferation of catheter-based and surgical interventional options. The 2026 guideline provides the first systematic framework for deploying these technologies within a risk-stratified context.

5.1 Systemic Thrombolysis

Systemic thrombolysis with full-dose intravenous tissue plasminogen activator (tPA) remains an important option for high-risk PE (Category E1) patients with cardiopulmonary failure and carries a Class 2a recommendation in this context. Its use is limited by significant bleeding risk, particularly intracranial hemorrhage, and it is contraindicated in numerous clinical scenarios. The guideline appropriately restricts systemic thrombolysis to situations where more targeted therapies are unavailable or when the patient’s condition demands immediate, aggressive clot lysis.

5.2 Catheter-Directed Thrombolysis (CDT)

CDT involves the delivery of lower-dose thrombolytics directly into the pulmonary vasculature via catheter, potentially reducing systemic bleeding exposure while maintaining thrombolytic efficacy. The guideline identifies CDT as a reasonable option for select patients in Categories D1-D2 and E1. The OPTALYSE PE and ULTIMA trials have provided supporting evidence for catheter-directed approaches, though robust randomized data comparing CDT to systemic thrombolysis in head-to-head trials remain an acknowledged evidence gap.

5.3 Mechanical Thrombectomy (MT)

Mechanical thrombectomy — including aspiration thrombectomy devices such as the Penumbra Indigo system and rheolytic thrombectomy — has gained considerable traction as a catheter-based intervention that avoids thrombolytic exposure entirely. The guideline issues a Class 2a recommendation for MT in Category E1 patients and a Class 2b recommendation for selected Category D1-D2 patients. Critically, MT receives a Class 3 recommendation (not recommended) in low-risk patients (Categories A through C1), providing important guardrails against overutilization. The guideline acknowledges that MT may be preferred over systemic thrombolysis in D1-E1 patients when bleeding risk is a concern, while noting that efficacy superiority over systemic thrombolysis has not been established.

5.4 Surgical Embolectomy

Surgical pulmonary embolectomy — involving operative extraction of thrombus from the pulmonary arteries — is recommended at experienced centers for high-risk patients with Category E PE, particularly when thrombolysis is contraindicated or has failed. The expanding availability of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) as a bridge to recovery or definitive therapy in refractory cardiopulmonary collapse is also recognized in the guideline.

6. Pulmonary Embolism Response Teams (PERTs): A Class 1 Mandate

Among the most practice-changing elements of the 2026 guideline is the elevation of Pulmonary Embolism Response Teams (PERTs) to a Class 1 recommendation. PERTs are structured multidisciplinary teams — typically including cardiologists, pulmonologists, emergency physicians, hematologists, interventional radiologists, and cardiac surgeons — convened to provide rapid, coordinated decision-making for patients with PE, particularly those in intermediate- and high-risk categories.

The guideline notes that PERT involvement improves the timeliness of care, facilitates appropriate risk stratification, guides selection and implementation of advanced therapies, and enhances follow-up care and clinician education. The PERT Consortium, established in 2015, has grown to encompass over 100 medical centers, with observational data suggesting that PERT activation is associated with faster anticoagulation initiation, greater utilization of LMWH over UFH, and fewer major bleeding events.

Critically, the guideline acknowledges that certain lower-risk patients — notably those in Category A or B with significant comorbidities such as intracranial hemorrhage — may also benefit from PERT consultation. This reflects the wisdom that the multidisciplinary expertise of a PERT can add value beyond the most critically ill patients, providing nuanced judgment in clinically complex situations where binary algorithms fall short.

7. Follow-up and Long-Term Management

The guideline introduces a structured, longitudinal follow-up framework that extends far beyond the acute phase of PE management — a domain historically underaddressed in clinical practice:

• Within 1 week of discharge: Communication or clinic evaluation to ensure anticoagulant adherence, assess for early complications, and address any immediate concerns.
• At 3 months: Formal reassessment to determine duration of anticoagulation therapy, evaluate for residual thromboembolic burden, assess biomarkers, and decide on further diagnostic workup.
• At each visit for at least 1 year: Screening for symptoms or functional limitations suggestive of chronic thromboembolic pulmonary disease (CTEPD), which can progress to chronic thromboembolic pulmonary hypertension (CTEPH) — a serious and potentially fatal complication characterized by persistent clot obstruction, pulmonary hypertension, and right heart failure.

The guideline also addresses several often-neglected dimensions of post-PE recovery:

• Psychological Health: Depression, anxiety, and post-traumatic stress disorder are acknowledged as common sequelae of acute PE. Clinicians are directed to screen for these conditions and incorporate mental health resources into follow-up care.
• Physical Activity: Early ambulation after anticoagulation initiation is encouraged to maintain cardiovascular conditioning and reduce venous stasis.
• Travel Precautions: Long-haul travel of 5 hours or more is identified as a risk factor for recurrence; recommendations include frequent movement, compression stockings, and limited long-distance travel in the at-risk period.
• Reproductive Health: Women of childbearing age with acute PE should receive counseling regarding safe contraceptive options and anticoagulation strategies in the event of future pregnancy.

8. Clinical Insights and Commentary

Beyond its explicit recommendations, the 2026 guideline embodies several important clinical insights that merit thoughtful commentary.

8.1 The Primacy of Physiology Over Anatomy

A central intellectual contribution of the guideline is its insistence that therapeutic decision-making should be anchored to physiopathological impact rather than anatomical clot burden. Massive central PE with preserved hemodynamics and normal RV function may warrant less aggressive intervention than a smaller peripheral clot associated with significant RV strain and incipient hemodynamic compromise. This shift challenges clinicians to move beyond radiological characterizations and toward integrative clinical assessment.

8.2 The Right Ventricle as the Therapeutic Target

The right ventricle is the primary determinant of outcomes in acute PE. RV dysfunction — manifested through elevated troponin, elevated BNP or NT-proBNP, RV dilation on echocardiography, and RV-to-LV diameter ratio on CTPA — is the physiological fulcrum upon which management decisions pivot. The guideline’s emphasis on serial RV assessment reflects the clinical reality that a patient in Category C can deteriorate rapidly to Category D or E if RV failure progresses, and that early recognition of this trajectory is life-saving.

8.3 Individualization Over Protocolization

The guideline wisely resists the temptation to reduce complex PE management to rigid algorithms. While the A-E Clinical Category system provides a powerful organizational framework, the document consistently emphasizes the importance of individualized decision-making, particularly in the use of advanced therapies. The recommendation that decisions in Category C should be restricted to cases of clinical progression following multidisciplinary PERT deliberation is a safeguard against the well-documented tendency to escalate interventions in intermediate-risk patients without robust evidence of benefit.

8.4 Closing the Loop on Long-Term Surveillance

The guideline’s structured follow-up framework addresses a significant gap in prior practice, where patients were often discharged with anticoagulation prescriptions but without clear plans for follow-up or monitoring. CTEPD, which may affect 3-5% of PE survivors, is a complication that is eminently detectable through systematic echocardiographic screening — yet frequently missed in the absence of protocol-driven surveillance. The mandated 1-year follow-up period for CTEPD screening represents one of the most clinically impactful recommendations in the document.

8.5 Equity and Disparities

Although the guideline itself does not extensively address health equity, the AHA Scientific Statement on Disparities in Current Pulmonary Embolism Management and Outcomes (March 2025) contextualizes an important parallel concern. Racial, socioeconomic, and geographic disparities in PE diagnosis, treatment access, and outcomes remain significant. The universal adoption of PERT infrastructure, DOAC access, and structured follow-up care has the potential to narrow these gaps — but only if implementation is accompanied by deliberate efforts to address systemic barriers.

8.6 Acknowledging Evidence Gaps

The writing committee candidly enumerates areas where evidence remains insufficient. These include validation of the new AHA/ACC Clinical Categories in prospective populations, integration of thrombus burden metrics and novel RV enlargement indices into risk stratification tools, and the need for head-to-head randomized controlled trials comparing catheter-based interventions with systemic thrombolysis in intermediate-high-risk PE. This intellectual honesty strengthens the document’s credibility and provides a clear research agenda for the field.

 

9. Comparison with the 2019 ESC Guidelines

The 2026 AHA/ACC guideline invites direct comparison with the 2019 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism, which defined the international standard for nearly a decade. The ACC Guideline Dissemination Workgroup explicitly prepared comparative tables highlighting the most important differences.

Key contrasts include the replacement of the ESC’s low/intermediate/high-risk taxonomy with the more granular five-category AHA/ACC Clinical Category system; the formal Class 1 recommendation for PERTs (which lacked equivalent emphasis in the ESC document); and the expanded algorithmic guidance for catheter-based interventions including mechanical thrombectomy, reflecting the technological advances of the intervening years. The 2026 guideline’s more detailed treatment of outpatient management, follow-up care, and special populations also represents a meaningful expansion beyond the 2019 ESC framework.

10. Conclusion

The 2026 AHA/ACC/Multisociety Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults represents a historic and comprehensive milestone in cardiovascular medicine. By introducing the AHA/ACC Acute PE Clinical Categories, mandating PERT-based multidisciplinary care, establishing DOACs as the preferred anticoagulant, defining criteria for advanced interventional therapies, and instituting a structured follow-up framework, the guideline provides clinicians with a precision road map for managing one of medicine’s most consequential emergencies.

The document’s most enduring contributions may lie not in its specific recommendations — which will inevitably evolve with emerging trial data — but in its philosophical underpinnings: that PE management must be physiology-driven, individualized, multidisciplinary, and longitudinal. As the evidence base continues to mature, the AHA/ACC Clinical Categories will require prospective validation, interventional technologies will demand rigorous comparative effectiveness data, and health systems will need to commit the resources necessary to build and sustain PERT infrastructure equitably.

For clinicians at the bedside, the 2026 guideline is a call to action — to move from pattern recognition to precision management, from acute stabilization to long-term stewardship, and from individual clinical judgment to coordinated multidisciplinary care. In doing so, it offers the best available roadmap for reducing the devastating toll that acute pulmonary embolism continues to exact on patients worldwide.

References

1. Creager MA, Barnes GD, Giri J, Mukherjee D, Jones WS, Burnett AE, et al. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026 Mar 24;153(12):e977-e1051. doi: 10.1161/CIR.0000000000001415. PMID: 41712677.
2. Creager MA, Barnes GD, Giri J, et al. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults. J Am Coll Cardiol. Published online Feb 19, 2026. doi: 10.1016/j.jacc.2025.11.005.
3. Dudzinski DM, Cibotti-Sun M, Moore MM. 2026 Acute Pulmonary Embolism Guideline-at-a-Glance. JACC. 2026. doi: 10.1016/j.jacc.2025.12.023.
4. American Heart Association / American College of Cardiology. First AHA/ACC Acute Pulmonary Embolism Guideline: Prompt Diagnosis and Treatment Are Key. Press Release. February 19, 2026. Available at: https://newsroom.heart.org/news/first-ahaacc-acute-pulmonary-embolism-guideline-prompt-diagnosis-and-treatment-are-key
5. American College of Cardiology. ACC, AHA Release First-Ever Guideline for Treatment and Management of Acute PE. February 2026. Available at: https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2026/02/17/14/32/ACC-AHA-Release-First-Ever-Guideline-For-Treatment-and-Management-of-Acute-PE
6. Guideline Central. ACC/AHA Evaluation and Management of Acute Pulmonary Embolism in Adults Guideline Summary. 2026. Available at: https://www.guidelinecentral.com/guideline/4983546/
7. Pharmacy Times. AHA/ACC Guidelines Introduce New Risk Stratification System for Acute Pulmonary Embolism. March 2026. Available at: https://www.pharmacytimes.com/view/aha-acc-guidelines-introduce-new-risk-stratification-system-for-acute-pulmonary-embolism
8. Endovascular Today. AHA/ACC Issue First Acute PE Guidelines with New Clinical Classification System. February 20, 2026. Available at: https://evtoday.com/news/ahaacc-issue-first-acute-pe-guidelines-with-new-clinical-classification-system
9. AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026. February 24, 2026. Available at: https://solaci.org/en/2026/02/24/aha-acc-guideline-on-the-management-of-acute-pulmonary-embolism-2026/
10. American Heart Association. 2026 Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults — Professional Heart Daily. Available at: https://professional.heart.org/en/science-news/2026-guideline-for-the-evaluation-and-management-of-acute-pulmonary-embolism-in-adults
11. American Heart Association. Disparities in Current Pulmonary Embolism Management and Outcomes. Scientific Statement. Circulation. March 2025.
12. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism. Eur Heart J. 2020;41(4):543-603. doi: 10.1093/eurheartj/ehz405.
13. Piazza G, Goldhaber SZ. Management of Submassive Pulmonary Embolism. Circulation. 2010;122(11):1124-1129.
14. PERT Consortium. Pulmonary Embolism Response Team (PERT) Consortium: Growth, Outcomes, and Future Directions. Chest. 2019;155(4):813-821.
15. Bikdeli B, Chatterjee S, Desai NR, et al. Inferior Vena Cava Filters to Prevent Pulmonary Embolism: Systematic Review and Meta-Analysis. J Am Coll Cardiol. 2017;70(13):1587-1597.